Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma
Phase I/II Trial of Systemic Administration of Edmonston Strain of Measles Virus, Genetically Engineered to Express NIS, With or Without Cyclophosphamide, in Patients With Recurrent or Refractory Multiple Myeloma
Sponsor: Mayo Clinic
A PHASE1/PHASE2 clinical study on Recurrent Plasma Cell Myeloma and Refractory Plasma Cell Myeloma, this trial is completed. The trial is conducted by Mayo Clinic and has accumulated 11 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Jan 2020 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
-
Jun 2019 — Jan 2020 [monthly]
Active Not Recruiting PHASE1_PHASE2
▶ Show 6 earlier versions
-
Feb 2019 — Jun 2019 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Aug 2018 — Feb 2019 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Aug 2018 [monthly]
Recruiting PHASE1_PHASE2
Status: Active Not Recruiting → Recruiting
-
May 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Feb 2017 — May 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Nov 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Mayo Clinic
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .